Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis. (2nd September 2022)

• Record Type: Journal Article
• Authors: Reich, Adam; Selmer, Johan; Galván, Jordi; Trebbien, Paw; Pi-Blanque, Aina; Danø, Anne; Stallknecht, Sandra Elkjaer; Bewley, Anthony
• Is Part Of: Current medical research and opinion. Volume 38:Number 9(2022)
• Page Start: 1521
• Page End: 1529
• Publication Date: 2022-09-02
• Subjects: Indirect comparison -- efficacy -- quality of life -- treatment satisfaction -- calcipotriol and betamethasone dipropionate -- cream -- foam -- gel -- psoriasis -- topical; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2022.2078099
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: To assess how the use of calcipotriol and betamethasone dipropionate (Cal/BDP) cream impacted efficacy, patients' quality of life (QoL), and treatment satisfaction versus Cal/BDP foam. Methods: Data from clinical trials of Cal/BDP cream and foam were analyzed, by applying the common anchor Cal/BDP gel. Efficacy was assessed by Physician Global Assessment (PGA) treatment success and ≥75% reduction in Psoriasis Area and Severity Index (PASI75 response); QoL by Dermatology Life Quality Index (DLQI); treatment satisfaction by Psoriasis Treatment Convenience Scale (PTCS) and Topical Product Usability Questionnaire (TPUQ). Results: Treatment with Cal/BDP cream was on par with foam on PGA treatment success (risk ratio (RR) for Cal/BDP cream versus foam: 0.80; 95%CI: 0.56, 1.14; p = .21) and PASI75 response (RR for Cal/BDP cream vs. foam: 0.85; 95%CI: 0.64, 1.13; p = .27) when assessed at the treatment duration of 8 weeks for Cal/BDP cream and 4 weeks for Cal/BDP foam. Treatment with Cal/BDP cream was associated with significantly greater treatment satisfaction versus foam on the domains: overall treatment satisfaction ( p = .01), "ease of application" ( p < .001), "lack of greasiness" ( p < .001), "moisturizing effect" ( p = .01), and almost significantly greater improvement on the domain "easily incorporated into daily routine" ( p = .07). Furthermore, there was a trend for greater DLQI improvement with cream versus foam when assessed at recommended treatment duration [mean difference (MD) for Cal/BDP cream vs. foam: −1.00; 95%CI: −2.20, 0.20; p = .10]. Conclusions: Indirect comparison analyses showed that Cal/BDP cream significantly improves treatment satisfaction and tends to improve QoL versus foam. Cal/BDP cream is on par with foam on efficacy.